Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
An oral pill maintains weight loss achieved by injectable therapy, potentially making long-term obesity treatment more accessible globally.
Orforglipron, an oral non-peptide GLP-1 receptor agonist, was tested as a maintenance strategy after injectable GLP-1RA (tirzepatide or semaglutide) in this Phase 3b RCT (n=376). It substantially maintained the weight loss achieved on injectable therapy compared to placebo, with treatment differences of 25.5% and 41.7% in the two cohorts, positioning oral GLP-1RA as a potential globally scalable transition strategy after injectable treatment.
What the study was
- Study design
- Phase 3b double-blind randomized placebo-controlled trial
- Population
- Adults with obesity previously treated with tirzepatide (cohort 1, N=205) or semaglutide (cohort 2, N=171) with achieved weight plateau
- Sample size
- 376
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Nature Medicine
Why it surfaced
Phase 3b RCT of oral GLP-1RA as maintenance after injectable obesity therapy — directly addresses the critical clinical problem of weight regain after stopping injectable GLP-1RAs. Large n=376, strong effect size (estimated treatment differences 25.5–41.7%), published Nat Med. Represents a potential paradigm shift enabling oral step-down from injectable for the hundreds of millions with obesity globally.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.